Durable natural killer cell responses after heterologous two-dose Ebola vaccination; Wagstaffe HR, et al. NPJ Vaccines. 2021. DOI: 10.1038/s41541-021-00280-0
Wagstaffe, HR (2019), The Effect of Viral Vaccines on Natural Killer Cell Effector Function. PhD (research paper style) thesis, London School of Hygiene & Tropical Medicine. DOI: https://doi.org/10.17037/PUBS.04653621
Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells; Tran TTP, et al. PLoS Pathog. 2018. DOI: 10.1371/journal.ppat.1007127
Vaccinating for natural killer cell effector functions; Wagstaffe HR, et al. Clin Transl Immunology. 2018. DOI: 10.1002/cti2.1010
NEWSLETTERS
8th EBOVAC2 Newsletter
The 8th EBOVAC2 newsletter is available here. This newsletter announces the European Commission Approval for Janssen's Ebola vaccine regimen.
7th EBOVAC2 Newsletter
Find out the news from the project in November 2017 here - with the announcement of the Ebovac2 4th General annual meeting planned in Nairobi (Kenya) next January.
6th EBOVAC2 Newsletter
Latest news from the project and interview with Dr Hervé Raoul, Director of Inserm's BSL-4 laboratory.
5th EBOVAC2 Newsletter
Find out what's going on in EBOVAC2, with a special focus on the Burkina Faso training session in January 2018.
4th EBOVAC2 Newsetter
News on EBOVAC2 December 2017, click here.
3rd EBOVAC2 Newsletter
News on EBOVAC2 in October 2017 click here. This issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz clinical site.
2nd EBOVAC2 Newsletter
Find out what's going on in EBOVAC2 here in June 2017.
1st EBOVAC2 Newsletter
Get a view on the EBOVAC2 news here in March 2016.
